HRP20191798T1 - Postupak liječenja jetrene encefalopatije - Google Patents

Postupak liječenja jetrene encefalopatije Download PDF

Info

Publication number
HRP20191798T1
HRP20191798T1 HRP20191798TT HRP20191798T HRP20191798T1 HR P20191798 T1 HRP20191798 T1 HR P20191798T1 HR P20191798T T HRP20191798T T HR P20191798TT HR P20191798 T HRP20191798 T HR P20191798T HR P20191798 T1 HRP20191798 T1 HR P20191798T1
Authority
HR
Croatia
Prior art keywords
biotin
use according
hepatic encephalopathy
patient
type
Prior art date
Application number
HRP20191798TT
Other languages
English (en)
Croatian (hr)
Inventor
Frédéric SEDEL
Original Assignee
Medday Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medday Pharmaceuticals filed Critical Medday Pharmaceuticals
Publication of HRP20191798T1 publication Critical patent/HRP20191798T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HRP20191798TT 2016-07-29 2017-07-28 Postupak liječenja jetrene encefalopatije HRP20191798T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305989.2A EP3275439A1 (en) 2016-07-29 2016-07-29 Method for treating hepatic encephalopathy
PCT/EP2017/069194 WO2018020010A1 (en) 2016-07-29 2017-07-28 Method for treating hepatic encephalopathy
EP17742782.0A EP3319601B1 (en) 2016-07-29 2017-07-28 Method for treating hepatic encephalopathy

Publications (1)

Publication Number Publication Date
HRP20191798T1 true HRP20191798T1 (hr) 2019-12-27

Family

ID=56618106

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191798TT HRP20191798T1 (hr) 2016-07-29 2017-07-28 Postupak liječenja jetrene encefalopatije

Country Status (24)

Country Link
US (2) US10117854B2 (enExample)
EP (2) EP3275439A1 (enExample)
JP (1) JP2019522030A (enExample)
KR (1) KR20190034550A (enExample)
AU (1) AU2017303346A1 (enExample)
BR (1) BR112019001178A2 (enExample)
CA (1) CA3031302A1 (enExample)
CY (1) CY1122348T1 (enExample)
DK (1) DK3319601T3 (enExample)
EA (1) EA201990413A1 (enExample)
ES (1) ES2751154T3 (enExample)
HK (1) HK1254833B (enExample)
HR (1) HRP20191798T1 (enExample)
HU (1) HUE046590T2 (enExample)
IL (1) IL264460B (enExample)
LT (1) LT3319601T (enExample)
MA (1) MA42419B1 (enExample)
ME (1) ME03520B (enExample)
PL (1) PL3319601T3 (enExample)
PT (1) PT3319601T (enExample)
RS (1) RS59300B1 (enExample)
SI (1) SI3319601T1 (enExample)
SM (1) SMT201900628T1 (enExample)
WO (1) WO2018020010A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3275439A1 (en) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
MX387893B (es) * 2018-04-18 2025-03-19 Alparis Sa De Cv Nuevas fases solidas de rifaximina.
CN116173182A (zh) * 2023-03-31 2023-05-30 苏州融析生物科技有限公司 醋酸格拉替雷药物组合物在肝硬化预防及治疗药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0788304B2 (ja) * 1988-03-05 1995-09-27 三生製薬株式会社 高アンモニア血症治療剤
US5814650A (en) * 1992-09-28 1998-09-29 Lifegroup S.P.A. Biotin amides able to control glucidic metabolisms under dysmetabolic conditions and relative therapeutical compositions
DE20202562U1 (de) * 2002-02-19 2002-05-23 Orthomol pharmazeutische Vertriebs GmbH, 40764 Langenfeld Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
US20040219188A1 (en) * 2003-05-02 2004-11-04 Comer Gail M. Composition and methods for nutritional management of patients with hepatic disease
US20130004545A1 (en) 2009-12-23 2013-01-03 Lupin Limited Slow release pharmaceutical compositions of iloperidone
FR2993780B1 (fr) * 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
FR2958166B1 (fr) 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
CA2910717C (en) 2013-04-29 2021-01-26 Assistance Publique - Hopitaux De Paris Biotin for use in treating x-linked adrenoleukodystrophy
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
CN105614851A (zh) * 2015-12-27 2016-06-01 劲膳美生物科技股份有限公司 肝性脑病医学配方食品
EP3275439A1 (en) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy

Also Published As

Publication number Publication date
MA42419A (fr) 2018-05-16
SMT201900628T1 (it) 2020-01-14
EP3275439A1 (en) 2018-01-31
CA3031302A1 (en) 2018-02-01
DK3319601T3 (da) 2019-11-18
PT3319601T (pt) 2019-09-18
EP3319601A1 (en) 2018-05-16
SI3319601T1 (sl) 2019-11-29
WO2018020010A1 (en) 2018-02-01
BR112019001178A2 (pt) 2019-04-30
MA42419B1 (fr) 2019-11-29
JP2019522030A (ja) 2019-08-08
US10117854B2 (en) 2018-11-06
CY1122348T1 (el) 2021-01-27
PL3319601T3 (pl) 2020-06-29
HK1254833B (en) 2020-05-22
IL264460B (en) 2021-06-30
US20180214417A1 (en) 2018-08-02
US10328059B2 (en) 2019-06-25
AU2017303346A1 (en) 2019-01-31
ES2751154T3 (es) 2020-03-30
ME03520B (me) 2020-04-20
HUE046590T2 (hu) 2020-03-30
RS59300B1 (sr) 2019-10-31
LT3319601T (lt) 2019-11-11
EA201990413A1 (ru) 2019-06-28
EP3319601B1 (en) 2019-08-28
IL264460A (en) 2019-02-28
US20190070150A1 (en) 2019-03-07
KR20190034550A (ko) 2019-04-02

Similar Documents

Publication Publication Date Title
RU2014121785A (ru) Композиция, содержащая виценин-2, обладающая благоприятным воздействием на неврологическую или когнитивную функцию
HRP20150260T1 (hr) Uporaba biotina za lijeäśenje multiple skleroze
HRP20230272T1 (hr) Postupci za liječenje cistične fibroze
NO20070887L (no) Kornformet farmasoytisk preparat med tidsbegrenset frigivelse for oral administrasjon, og intraoral hurtig desintegrerende tablett som inneholder preparatet
Tuite et al. Recent developments in the pharmacological treatment of Parkinson’s disease
FI3562486T3 (fi) Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
HRP20191798T1 (hr) Postupak liječenja jetrene encefalopatije
JP2018513171A5 (enExample)
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
JP2018507243A5 (enExample)
Abad et al. Effect of Matricaria chamomilla hydroalcoholic extract on cisplatin-induced neuropathy in mice
JP2015522630A5 (enExample)
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
Moraes et al. Medicinal plant Combretum leprosum mart ameliorates motor, biochemical and molecular alterations in a Parkinson's disease model induced by MPTP
RU2004105263A (ru) Фармацевтические композиции, содержащие тербинафин, и их применение
JP2019530706A5 (enExample)
RU2007103306A (ru) Композиции на основе ризедроната и способы их применения
HRP20191491T1 (hr) Biotin za liječenje demijelinizirajućih neuropatija
JP2016505050A5 (enExample)
JP2019522030A5 (enExample)
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use
JP2020509072A5 (enExample)
MX2023003097A (es) Composiciones farmaceuticas que comprenden un oligonucleotido antisentido para administracion oral.
JP2019535830A5 (enExample)